The global recombinant proteins market is valued at 125.8 billion in 2020 and is expected to register a CAGR of 11.2% over the forecast period (2021-2026).
The growth of the recombinant protein market is attributed owing to increased expenditure in R&D, the growing prevalence of chronic diseases, rising inclination toward biologics and biosimilars, and advanced recombinant products.
According to OECD, Health at a Glance, 2019 report, almost one-third of people aged 15 years and over reported living with two or more chronic conditions, which include cancer, heart attack and stroke, chronic respiratory problems, and diabetes, on average across 27 OECD countries globally. In Germany and Finland, the prevalence of chronic diseases rises to almost one in two.
Investments have been increasing in research and development, leading to the introduction of new protein therapeutics, which has significantly contributed to the growth and development of the market studied. For instance, in Jnaury 2020, Airway Therapeutics, Inc., recived USD 15.5 million Series C financing round for development of company's AT-100 a novel recombinant human protein rhSP-D an investigational preventive treatment for the serious respiratory disease bronchopulmonary dysplasia (BPD) .
Moreover, there has been a significant focus on the development of recombinant protien based vaccines and therapies for the treatment COVID-19, which is established as a serious burden on global healthcare economy currently. For instance, in October 2020, Novavax, Inc recieved USD 4million from Coalition for Epidemic Preparedness Innovations (CEPI) to accelerate the development of a COVID-19 vaccine based on its proprietary recombinant protein nanoparticle technology platform.
However, Recombinant protein production is found to be a time-consuming procedure, which also requires high cost and maintenance coupled withe regulatiry and safety concerns associated with Recombinant protein production are likley to hamper the market growth during the forecast period.
Key Market Trends
Antibody Segment is Expected to Grow at the Fastest Rate, Over the Forecast Period
The recombinant antibody production procedure involves the cloning of antibody gene libraries into phage vectors and allowing the phages to infect a host cell line. The host cells then produce daughter phages, which express the recombinant antibodies on their surfaces. The genes can be inserted into an expression system and the antibodies can be produced in large quantities after a process of selection for antibodies with the desired characteristics.
This procedure has been gaining prominence in recent times and many companies have adopted this innovative method to apply to various applications. In April 2019, the Immunoprecise Antibodies Ltd. announced the expansion of its service offerings in therapeutic antibody discovery to select rare, fully human antibodies using its trademark DeepDisplay, a combination of transgenic animal immunization and custom phage display antibody selection.
The market players are adopting various growth strategies in order to excel in the respective field. For instance, In June 2020, Recombinant Antibody Network (RAN), a consortium comprising research groups from UC San Francisco, the University of Chicago, and the University of Toronto, has entered into research collaboration with Celgene , a Bristol Myers Squibb company to create and develop high-performance recombinant antibodies against diverse targets in human cells.
Companies are also involved in development of recombinant antibodies for COVID-19 infection. In September 2020, GigaGen Inc. in collaboration with Waisman Biomanufacturing and Goodwin Biotechnology, Inc. initiated large-scale manufacturing of its first-in-class recombinant hyperimmune drug GIGA-2050 for treatment of COVID-19.
North American Region Holds the Largest Market Share of the Market
North America is expected to lead the global recombinant protein market, owing to the increasing expenditure in research coupled with the presence of healthcare infrastructure and several major market players. In 2018, Grifols received U.S. FDA approval to relocate existing immunodiagnostic manufacturing operations to a new consolidated manufacturing facility (CMF) in Emeryville, California for the production of recombinant proteins.
The chronic diseases that are on the rise across the region are creating a huge demand for recombinant protein therapies, as recombinant proteins are among the proven solutions for treating such diseases. According to GLOBOCAN, 1,95,499 new cancer cases were diagnosed, and 90,222 deaths were reported due to cancer in Mexico in the year 2020.
Furthermore, the presence of the key players of the market studied and their continuous launches and developments in the region indicate that the market is well-established and is expected to remain so over the forecast period. For instance, in June 2020, Sandoz Canada Inc., a division of Novartis AG received Health Canada approval for its Ziextenzo a long-acting recombinant human granulocyte colony-stimulating factor (r-metHuG-CSF) indicated to decrease the incidence of infection in patients with non-myeloid malignancies.
During this pandemic period, several big pharmaceutical companies are investing in recombinant DNA technologies and proteins to address the situation. In April 2020, Sanofi and GSK collaborated to develop vaccines based upon Sanofi recombinant forms of S-protein COVID-19 antigen and GSK's adjuvant technology. In addition, certain acquisitions are also happening to boost R&D towards the development of recombinant proteins.
The recombinant protein market consists of several major players, including Eli Lilly and Company, Merck KGaA, and Novo Nordisk AS, among others. The companies are implementing certain strategic initiatives, such as mergers, new product launches, acquisitions, and partnerships, which help them in strengthening their market position.
For instance, in November 2020, Eli Lilly and Company recieved Emergency Use Authorization (EUA) investigational neutralizing antibody bamlanivimab (LY-CoV555) 700 mg for for the treatment of mild to moderate COVID-19 in adults and pediatric patients.
In July 2020, Richcore LifeSciences, a Bengaluru-based biotechnology company established its new manufacturing facility in Tumkur, Karnataka for production of recombinant proteins.
Reasons to Purchase this report:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
TABLE OF CONTENTS
- 1.1 Study Deliverables
- 1.2 Study Assumptions
- 1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
- 4.1 Market Overview
- 4.2 Market Drivers
- 4.2.1 Increasing Expenditure in Research and Development
- 4.2.2 Growing Burden of Chronic Diseases
- 4.2.3 Rising Inclination toward Biologics and Biosimilars
- 4.2.4 Technological Advancements in Recombinant Products
- 4.3 Market Restraints
- 4.3.1 Expensive and Time-consuming Production Process
- 4.3.2 Safety Issues
- 4.4 Porter's Five Forces Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
- 5.1 By Type of Product
- 5.1.1 Hormone
- 5.1.2 Growth Factor
- 5.1.3 Antibody
- 5.1.4 Enzyme
- 5.1.5 Other Type of Products
- 5.2 By Application
- 5.2.1 Research Application
- 5.2.2 Therapeutic Use
- 5.2.3 Biotechnology Industry
- 5.3 Geography
- 5.3.1 North America
- 220.127.116.11 United States (By Type of Product, and By Application)
- 18.104.22.168 Canada (By Type of Product, and By Application)
- 22.214.171.124 Mexico (By Type of Product, and By Application)
- 5.3.2 Europe
- 126.96.36.199 Germany (By Type of Product, and By Application)
- 188.8.131.52 United Kingdom (By Type of Product, and By Application)
- 184.108.40.206 France (By Type of Product, and By Application)
- 220.127.116.11 Italy (By Type of Product, and By Application)
- 18.104.22.168 Spain (By Type of Product, and By Application)
- 22.214.171.124 Rest of Europe (By Type of Product, and By Application)
- 5.3.3 Asia-Pacific
- 126.96.36.199 China (By Type of Product, and By Application)
- 188.8.131.52 Japan (By Type of Product, and By Application)
- 184.108.40.206 India (By Type of Product, and By Application)
- 220.127.116.11 Australia (By Type of Product, and By Application)
- 18.104.22.168 South Korea (By Type of Product, and By Application)
- 22.214.171.124 Rest of Asia-Pacific (By Type of Product, and By Application)
- 5.3.4 Middle East and Africa
- 126.96.36.199 GCC (By Type of Product, and By Application)
- 188.8.131.52 South Africa (By Type of Product, and By Application)
- 184.108.40.206 Rest of Middle East and Africa (By Type of Product, and By Application)
- 5.3.5 South America
- 220.127.116.11 Brazil (By Type of Product, and By Application)
- 18.104.22.168 Argentina (By Type of Product, and By Application)
- 22.214.171.124 Rest of South America (By Type of Product, and By Application)
6 COMPETITIVE LANDSCAPE
- 6.1 Company Profiles
- 6.1.1 Abcam PLC
- 6.1.2 Amgen Inc.
- 6.1.3 Bio-Rad Laboratories Inc.
- 6.1.4 Eli Lilly and Company
- 6.1.5 Merck KGaA
- 6.1.6 Novo Nordisk AS
- 6.1.7 Sanofi SA
- 6.1.8 Thermo Fisher Scientific Inc.
- 6.1.9 Novartis AG
- 6.1.10 GeneTex, Inc.
- 6.1.11 Novavax, Inc
- 6.1.12 GigaGen Inc
- 6.1.13 Biocon
7 MARKET OPPORTUNITIES AND FUTURE TRENDS